Cargando…

Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure

BACKGROUND: Recent studies have suggested a possible association between heparin treatment at the time of cell-free DNA (cfDNA) testing and a non-reportable result. However, these studies lack of proper methodology and had a low level of proof to firmly incriminate heparin. Our objective was to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabi, Yohann, Guterman, Sarah, Jani, Jacques C., Letourneau, Alexandra, Demain, Adèle, Kleinfinger, Pascale, Lohmann, Laurence, Costa, Jean-Marc, Benachi, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276207/
https://www.ncbi.nlm.nih.gov/pubmed/30509296
http://dx.doi.org/10.1186/s12967-018-1705-2
_version_ 1783377968557457408
author Dabi, Yohann
Guterman, Sarah
Jani, Jacques C.
Letourneau, Alexandra
Demain, Adèle
Kleinfinger, Pascale
Lohmann, Laurence
Costa, Jean-Marc
Benachi, Alexandra
author_facet Dabi, Yohann
Guterman, Sarah
Jani, Jacques C.
Letourneau, Alexandra
Demain, Adèle
Kleinfinger, Pascale
Lohmann, Laurence
Costa, Jean-Marc
Benachi, Alexandra
author_sort Dabi, Yohann
collection PubMed
description BACKGROUND: Recent studies have suggested a possible association between heparin treatment at the time of cell-free DNA (cfDNA) testing and a non-reportable result. However, these studies lack of proper methodology and had a low level of proof to firmly incriminate heparin. Our objective was to investigate further the relationship between heparin treatment and cfDNA test results. METHODS: Two complementary approaches were used for the demonstration. First, we conducted a retrospective analysis of a cohort of patients with a singleton pregnancy, screened for aneuploidies by using cfDNA, but with a non-reportable cfDNA result. We included patients between 2013 and 2016 including the patients from the DEPOSA study as controls. CfDNA testing was performed by massive parallel sequencing by using a whole-genome approach. A multiple logistic regression was used to account for the influence of the variables included. Second, we performed in vitro experiments on mimic samples containing increased concentrations of heparin. RESULTS: Of 9867 singleton pregnancies tested during the inclusion period, 58 (0.59%) had a non-reportable result and were compared to 295 control patients. Fifteen (25.9%) and 20 (6.8%) patients were treated with heparin in the group with a non-reportable cfDNA result and with a successful assay, respectively. In multivariable analysis, an increased calculated risk at the first-trimester combined screening (OR 28.8 CI 9.76–85.15, p < 0.001), maternal weight (OR 1.03, CI 1.01–1.06, p = 0.01), and the presence of an autoimmune disease (OR 10.38, CI 1.62–66.53, p = 0.01) were the only characteristics associated with a non-reportable result. In vitro experiments showed that heparin had no impact on fetal fraction measurement or the final result, no matter what the dose tested. CONCLUSIONS: Treatment by heparin had no impact on cfDNA screening test for aneuploidies, while the presence of an autoimmune disorder is an independent predictor of a non-reportable result.
format Online
Article
Text
id pubmed-6276207
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62762072018-12-06 Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure Dabi, Yohann Guterman, Sarah Jani, Jacques C. Letourneau, Alexandra Demain, Adèle Kleinfinger, Pascale Lohmann, Laurence Costa, Jean-Marc Benachi, Alexandra J Transl Med Research BACKGROUND: Recent studies have suggested a possible association between heparin treatment at the time of cell-free DNA (cfDNA) testing and a non-reportable result. However, these studies lack of proper methodology and had a low level of proof to firmly incriminate heparin. Our objective was to investigate further the relationship between heparin treatment and cfDNA test results. METHODS: Two complementary approaches were used for the demonstration. First, we conducted a retrospective analysis of a cohort of patients with a singleton pregnancy, screened for aneuploidies by using cfDNA, but with a non-reportable cfDNA result. We included patients between 2013 and 2016 including the patients from the DEPOSA study as controls. CfDNA testing was performed by massive parallel sequencing by using a whole-genome approach. A multiple logistic regression was used to account for the influence of the variables included. Second, we performed in vitro experiments on mimic samples containing increased concentrations of heparin. RESULTS: Of 9867 singleton pregnancies tested during the inclusion period, 58 (0.59%) had a non-reportable result and were compared to 295 control patients. Fifteen (25.9%) and 20 (6.8%) patients were treated with heparin in the group with a non-reportable cfDNA result and with a successful assay, respectively. In multivariable analysis, an increased calculated risk at the first-trimester combined screening (OR 28.8 CI 9.76–85.15, p < 0.001), maternal weight (OR 1.03, CI 1.01–1.06, p = 0.01), and the presence of an autoimmune disease (OR 10.38, CI 1.62–66.53, p = 0.01) were the only characteristics associated with a non-reportable result. In vitro experiments showed that heparin had no impact on fetal fraction measurement or the final result, no matter what the dose tested. CONCLUSIONS: Treatment by heparin had no impact on cfDNA screening test for aneuploidies, while the presence of an autoimmune disorder is an independent predictor of a non-reportable result. BioMed Central 2018-12-03 /pmc/articles/PMC6276207/ /pubmed/30509296 http://dx.doi.org/10.1186/s12967-018-1705-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Dabi, Yohann
Guterman, Sarah
Jani, Jacques C.
Letourneau, Alexandra
Demain, Adèle
Kleinfinger, Pascale
Lohmann, Laurence
Costa, Jean-Marc
Benachi, Alexandra
Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure
title Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure
title_full Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure
title_fullStr Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure
title_full_unstemmed Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure
title_short Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure
title_sort autoimmune disorders but not heparin are associated with cell-free fetal dna test failure
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276207/
https://www.ncbi.nlm.nih.gov/pubmed/30509296
http://dx.doi.org/10.1186/s12967-018-1705-2
work_keys_str_mv AT dabiyohann autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT gutermansarah autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT janijacquesc autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT letourneaualexandra autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT demainadele autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT kleinfingerpascale autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT lohmannlaurence autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT costajeanmarc autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure
AT benachialexandra autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure